TLR9-binding chimeric antigen receptors

Patent metadata

Field	Value
Publication number	US-11286306-B2
Application number	US-201716467286-A
Country	US
Kind code	B2
Filing date	Dec 8, 2017
Priority date	Dec 9, 2016
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill cancer cells that express TLR9 on their surface. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a TLR9-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

First claim

What is claimed is:

1. A chimeric antigen receptor (CAR) polypeptide, comprising a TLR9-binding region, a transmembrane domain, a signaling domain, and a co-stimulatory signaling region,
wherein the TLR9-binding region is a single-chain variable fragment (scFv) of an antibody that specifically binds TLR9,
wherein the anti-TLR9 scFv comprises a variable heavy (V H ) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V L ) domain having CDR1, CDR2 and CDR3 sequences,
wherein the CDR1 sequence of the V H domain comprises the amino acid sequence TAGMQ (SEQ ID NO:1),
wherein the CDR2 sequence of the V H domain comprises the amino acid sequence WINTHSGEPKYAEDFKG (SEQ ID NO:2),
wherein the CDR3 sequence of the V H domain comprises the amino acid sequence GDSSGYGAWFAY (SEQ ID NO:3),
wherein the CDR1 sequence of the V L domain comprises the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO:4
wherein the CDR2 sequence of the V L domain comprises the amino acid sequence DTNNRAP (SEQ ID NO:5), and
wherein the CDR3 sequence of the V L domain comprises the amino acid sequence ALWCSNHWV (SEQ ID NO:6).

2. The CAR polypeptide of claim 1 , wherein the costimulatory signaling region comprises the cytoplasmic domain of a costimulatory molecule selected from the group consisting of CD27, CD28, CD7, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and any combination thereof.

3. The CAR polypeptide of claim 1 , wherein the CAR polypeptide is defined by the formula:
SP-TLR9-HG-TM-CSR-SD; or
SP-TLR9-HG-TM-SD-CSR
wherein “SP” represents a signal peptide,
wherein “TLR9” represents the TLR9-binding region,
wherein “HG” represents an optional hinge domain,
wherein “TM” represents a transmembrane domain,
wherein “CSR” represents a co-stimulatory signaling region,
wherein “SD” represents the signaling domain, and
wherein “-” represents a peptide bond, linker, or spacer.

4. The CAR polypeptide of claim 3 , wherein the spacer linking the TLR9-binding domain to the hinge domain comprises the amino acid sequence SEQ ID NO:11 or SEQ ID NO:12.

5. The CAR polypeptide of claim 3 , wherein the spacer linking the transmembrane domain to the signal signaling domain comprises an LCK-binding region of CD8alpha.

6. The CAR polypeptide of claim 5 , wherein the LCK-binding region has the amino acid sequence SEQ ID NO:31.

7. The CAR polypeptide of claim 1 , wherein the signaling domain comprises a CD3 zeta (CD3ζ) signaling domain.

8. The CAR polypeptide of claim 1 , wherein the anti-TLR9 scFv V H domain comprises the amino acid sequence SEQ ID NO:7 or SEQ ID NO:8.

9. The CAR polypeptide of claim 1 , wherein the anti-TLR9 scFv V L domain comprises the amino acid sequence SEQ ID NO:9 or SEQ ID NO:10.

10. An isolated nucleic acid sequence encoding the CAR polypeptide of claim 1 .

11. A vector comprising the isolated nucleic acid sequence of claim 10 .

12. A cell comprising the vector of claim 11 .

13. The cell of claim 12 , wherein the cell is selected from the group consisting of an aβT cell, yδT cell, a Natural Killer (NK) cell, a Natural Killer T (NKT) cell, a B cell, an innate lymphoid cell (ILC), a cytokine induced killer (CIK) cell, a cytotoxic T lymphocyte (CTL), a lymphokine activated killer (LAK) cell, a regulatory T cell, or any combination thereof.

14. A method of providing an anti-tumor immunity in a subject with a TLR 9 -expressing cancer, the method comprising administering to the subject an effective amount of an immune effector cell genetically modified to express the CAR polypeptide of claim 1 , thereby providing an anti-tumor immunity in the mammal.

15. The method of claim 14 , wherein the immune effector cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.

16. The method of claim 14 further comprising administering to the subject a checkpoint inhibitor.

17. The method of claim 16 , wherein the checkpoint inhibitor comprises an anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, or a combination thereof.

Assignees

• H Lee Moffitt Cancer Ct & Res

Inventors

• Abate-Daga Daniel
• List Alan F
• Wei Sheng

Classifications

• C07K16/2896 Primary

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title